Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations.

Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations.

In the search for effective vaccines against intracellular pathogens such as HIV, tuberculosis and malaria, recombinant viral vectors are increasingly being used to boost previously primed T cell responses. Published data have shown prime-boost vaccination with BCG-MVA85A (modified vaccinia virus An...

Descripció completa

Dades bibliogràfiques
Autors principals:	Beveridge, N, Price, D, Casazza, J, Pathan, A, Sander, C, Asher, T, Ambrozak, DR, Precopio, M, Scheinberg, P, Alder, N, Roederer, M, Koup, R, Douek, D, Hill, A, Mcshane, H
Format:	Journal article
Idioma:	English
Publicat:	2007

Ítems similars

Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
per: Whelan, K, et al.
Publicat: (2009)

Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-beta1.
per: Fletcher, H, et al.
Publicat: (2008)

Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials.
per: Mcshane, H, et al.
Publicat: (2005)

Polyfunctional T cell responses are a hallmark of HIV-2 infection.
per: Duvall, MG, et al.
Publicat: (2008)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A.
per: Kathryn T. Whelan, et al.
Publicat: (2011-01-01)

CD4 T cell response to MVA85A vaccination against Mycobacterium tuberculosis in healthy HIV-infected adults
per: Beveridge, N, et al.
Publicat: (2011)

A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults
per: Minassian, A, et al.
Publicat: (2011)

A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity
per: Rowland, R, et al.
Publicat: (2012)

DEVELOPING A NEW TB VACCINE: BOOSTING BCG WITH MVA85A
per: Mcshane, H
Publicat: (2008)

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals.
per: Sander, C, et al.
Publicat: (2009)

Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing Antigen 85A: Different Boosting Intervals and Implications for Efficacy Trials
per: Pathan, A, et al.
Publicat: (2007)

Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials.
per: Pathan, A, et al.
Publicat: (2007)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.
per: Pathan, A, et al.
Publicat: (2012)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
per: Pathan, A, et al.
Publicat: (2012)

Investigating the induction of vaccine-induced Th17 and regulatory T cells in healthy, Mycobacterium bovis BCG-immunized adults vaccinated with a new tuberculosis vaccine, MVA85A.
per: de Cassan, S, et al.
Publicat: (2010)

Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel Mycobacterium tuberculosis vaccine MVA85A.
per: Griffiths, K, et al.
Publicat: (2011)

Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel mycobacterium tuberculosis vaccine MVA85A
per: Griffiths, K, et al.
Publicat: (2011)

Optimising the vaccine strategy of BCG, ChAdOx1 85A, and MVA85A for tuberculosis control
per: Wajja, A, et al.
Publicat: (2024)

Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants.
per: Scriba, T, et al.
Publicat: (2011)

Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials.
per: Ansar A Pathan, et al.
Publicat: (2007-10-01)

Correction: Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing Antigen 85A: Different Boosting Intervals and Implications for Efficacy Trials.
per: Ansar A. Pathan, et al.
Publicat: (2011-01-01)

Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate TB vaccine, MVA85A, alone and in combination
per: Harris, S, et al.
Publicat: (2013)

Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate tuberculosis vaccine, MVA85A, alone and in combination.
per: Harris, SA, et al.
Publicat: (2014)

Investigating the Induction of Vaccine-Induced Th17 and Regulatory T Cells in Healthy, Mycobacterium bovis BCG Immunized Adults Vaccinated with a New Tuberculosis Vaccine, MVA85A (vol 17, pg 1066, 2010)
per: de Cassan, S, et al.
Publicat: (2011)

Investigating the induction of vaccine-induced Th17 and regulatory T cells in healthy, Mycobacterium bovis BCG immunized adults vaccinated with a new tuberculosis vaccine, MVA85A (Clinical and Vaccine Immunology (2010) 17, 7, (1066-1073))
per: De Cassan, S, et al.
Publicat: (2011)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A
Publicat: (2011-01-01)

Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial
per: Manjaly Thomas, Z, et al.
Publicat: (2019)

Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel Mycobacterium tuberculosis vaccine MVA85A.
per: Kristin L Griffiths, et al.
Publicat: (2011-01-01)

Comparison of the safety and immunogenicity of a candidate TB vaccine, MVA85A, given by the intramuscular or intradermal route in BCG-vaccinated adults
per: Harris, S, et al.
Publicat: (2011)

Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial.
per: Rowland, R, et al.
Publicat: (2013)

Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.
per: Zita-Rose Manjaly Thomas, et al.
Publicat: (2019-04-01)

Differential cytokine levels in adults induced by a Novel candidate TB boost vaccine, MVA85A-according to previous BCG vaccination status
per: Owiafe, P, et al.
Publicat: (2012)

Phase I/II clinical trial of MVA85A in individuals with latent tuberculosis: The first subunit TB vaccine in clinical trial
per: Sander, C, et al.
Publicat: (2005)

Effects of MVA85A vaccine on tuberculosis challenge in animals: systematic review
per: Mcshane, H, et al.
Publicat: (2016)

Correction: MVA.85A Boosting of BCG and an Attenuated, Deficient Vaccine Both Show Protective Efficacy Against Tuberculosis in Rhesus Macaques.
per: Frank A. W. Verreck, et al.
Publicat: (2011-01-01)

Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trial
per: Wajja, A, et al.
Publicat: (2023)

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans.
per: McShane, H, et al.
Publicat: (2004)

MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques.
per: Verreck, F, et al.
Publicat: (2009)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial
per: Wajja, A, et al.
Publicat: (2017)

Evaluating aerosol administration of a candidate TB vaccine MVA85A
per: Thomas, Z, et al.
Publicat: (2014)